Value of extracellular vesicle DNA as an indicator of tumor liquid biopsy molecules

doi:10.3760/cma.j.cn371439-20230523-00126

Abstract

Abstract:

Extracellular vesicle （EV） is widely distributed and fully involved in the regulation of various aspects of cellular physiology. As active carriers of molecular biomarkers and mediators of intercellular communication，EV is involved in the occurrence，development，metastasis，drug resistance and other links of tumors. The EV，which can be obtained from a variety of body fluids and are highly homologous to tissues，plays an important role in the maintenance of cell homeostasis and the exchange of substances and information between cells，thus becoming an ideal biomarker for tumor diagnosis and treatment. In the emerging liquid biopsy application，EV DNA can be used as a molecular marker for the diagnosis and prognosis evaluation of many kinds of tumors，and it is the most potential molecular marker of liquid biopsy in the field of tumor diagnosis and treatment.

Key words: Extracellular vesicles, Neoplasms, DNA

Yin Shuhui, Wen Rong, Miao Shufang. Value of extracellular vesicle DNA as an indicator of tumor liquid biopsy molecules[J]. Journal of International Oncology, 2023, 50(11): 668-671.

References 27

[1]	Lee JS, Hur JY, Kim IA, et al. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA[J]. BMC Cancer, 2018, 18(1): 1236. DOI: 10.1186/s12885-018-5138-3. pmid: 30526536
[2]	Perdomo S, Avogbe PH, Foll M, et al. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches[J]. Oncotarget, 2017, 8(42): 72621-72632. DOI: 10.18632/oncotarget.20004. pmid: 29069814
[3]	Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology[J]. Crit Rev Oncol Hematol, 2019, 141: 36-42. DOI: 10.1016/j.critrevonc.2019.06.005. pmid: 31212145
[4]	Russano M, Napolitano A, Ribelli G, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples[J]. J Exp Clin Cancer Res, 2020, 39(1): 95. DOI: 10.1186/s13046-020-01601-2. pmid: 32460897
[5]	Zhou B, Xu K, Zheng X, et al. Application of exosomes as liquid biopsy in clinical diagnosis[J]. Signal Transduct Target Ther, 2020, 5(1): 144. DOI: 10.1038/s41392-020-00258-9.
[6]	Valencia K, Montuenga LM. Exosomes in liquid biopsy: the nanometric world in the pursuit of precision oncology[J]. Cancers (Basel), 2021, 13(9): 2147. DOI: 10.3390/cancers13092147.
[7]	Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis[J]. Cells, 2019, 8(7): 727. DOI: 10.3390/cells8070727.
[8]	Whiteside TL. Tumor-derived exosomes and their role in cancer progression[J]. Adv Clin Chem, 2016, 74: 103-141. DOI: 10.1016/bs.acc.2015.12.005. pmid: 27117662
[9]	Amintas S, Vendrely V, Dupin C, et al. Next-generation cancer biomarkers: extracellular vesicle DNA as a circulating surrogate of tumor DNA[J]. Front Cell Dev Biol, 2021, 8: 622048. DOI: 10.3389/fcell.2020.622048.
[10]	Kim IA, Hur JY, Kim HJ, et al. Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma[J]. J Pathol Transl Med, 2020, 54(6): 453-461. DOI: 10.4132/jptm.2020.08.13. pmid: 33027851
[11]	Akuma P, Okagu OD, Udenigwe CC. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds[J]. Front Sustain Food Syst, 2019, 3: 23. DOI: 10.3389/fsufs.2019.00023.
[12]	Gorgannezhad L, Umer M, Islam MN, et al. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies[J]. Lab Chip, 2018, 18(8): 1174-1196. DOI: 10.1039/C8LC00100F. pmid: 29569666
[13]	Park J, Lee C, Eom JS, et al. Detection of EGFR mutations using bronchial washing-derived extracellular vesicles in patients with non-small-cell lung carcinoma[J]. Cancers (Basel), 2020, 12(10): 2822. DOI: 10.3390/cancers12102822.
[14]	Maire CL, Fuh MM, Kaulich K, et al. Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification[J]. Neuro Oncol, 2021, 23(7): 1087-1099. DOI: 10.1093/neuonc/noab012.
[15]	Qu X, Li Q, Yang J, et al. Double-stranded DNA in exosomes of malignant pleural effusions as a novel DNA source for EGFR mutation detection in lung adenocarcinoma[J]. Front Oncol, 2019, 9: 931. DOI: 10.3389/fonc.2019.00931. pmid: 31608233
[16]	Song Z, Cai Z, Yan J, et al. Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma[J]. Transl Lung Cancer Res, 2019, 8(4): 392-400. DOI: 10.21037/tlcr.2019.08.14.
[17]	Lee DH, Yoon H, Park S, et al. Urinary exosomal and cell-free DNA detects somatic mutation and copy number alteration in urothelial carcinoma of bladder[J]. Sci Rep, 2018, 8(1): 14707. DOI: 10.1038/s41598-018-32900-6. pmid: 30279572
[18]	Hur JY, Kim HJ, Lee JS, et al. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients[J]. Mol Cancer, 2018, 17(1): 15. DOI: 10.1186/s12943-018-0772-6. pmid: 29374476
[19]	Rimmer MP, Gregory CD, Mitchell RT. Extracellular vesicles in urological malignancies[J]. Biochim Biophys Acta Rev Cancer, 2021, 8, 1876(1): 188570. DOI: 10.1016/j.bbcan.2021.188570.
[20]	Kitai Y, Kawasaki T, Sueyoshi T, et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity[J]. J Immunol, 2017, 198(4): 1649-1659. DOI: 10.4049/jimmunol.1601694. pmid: 28069806
[21]	Torralba D, Baixauli F, Villarroya-Beltri C, et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts[J]. Nat Commun, 2018, 9(1): 2658. DOI: 10.1038/s41467-018-05077-9. pmid: 29985392
[22]	Lian Q, Xu J, Yan S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation[J]. Cell Res, 2017, 27(6): 784-800. DOI: 10.1038/cr.2017.54. pmid: 28409562
[23]	Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy[J]. Breast Cancer Res, 2019, 21(1): 21. DOI: 10.1186/s13058-019-1109-0. pmid: 30728048
[24]	Castellanos-Rizaldos E, Zhang X, Tadigotla VR, et al. Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients[J]. Oncotarget, 2019, 10(30): 2911-2920. DOI: 10.18632/oncotarget.26885. pmid: 31080561
[25]	Thakur K, Singh MS, Feldstein-Davydova S, et al. Extracellular vesicle-derived DNA vs. cfDNA as a biomarker for the detection of colon cancer[J]. Genes (Basel), 2021, 12(8): 1171. DOI: 10.3390/genes12081171.
[26]	Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients[J]. Ann Oncol, 2017, 28(4):741-747. DOI: 10.1093/annonc/mdx004. pmid: 28104621
[27]	Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer[J]. Gastroenterology, 2019, 156(1): 108-118.e4. DOI: 10.1053/j.gastro.2018.09.022. pmid: 30240661